CSTL CASTLE BIOSCIENCES INC

Nasdaq castlebiosciences.com


$ 22.41 $ -0.16 (-0.71 %)    

Tuesday, 14-Oct-2025 15:42:09 EDT
QQQ $ 598.24 $ 3.05 (0.51 %)
DIA $ 462.67 $ 5.56 (1.22 %)
SPY $ 661.93 $ 4.64 (0.71 %)
TLT $ 90.87 $ 0.23 (0.25 %)
GLD $ 381.01 $ 2.69 (0.71 %)
$ 22.81
$ 22.57
$ 22.35 x 37
$ 22.45 x 20
$ 22.33 - $ 22.78
$ 14.59 - $ 35.84
186,557
na
661.68M
$ 1.64
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-04-2025 06-30-2025 10-Q
2 05-05-2025 03-31-2025 10-Q
3 02-27-2025 01-01-1970 10-K
4 11-04-2024 09-30-2024 10-Q
5 08-05-2024 06-30-2024 10-Q
6 05-02-2024 03-31-2024 10-Q
7 02-28-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-02-2023 06-30-2023 10-Q
10 05-03-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-02-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-08-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-10-2021 03-31-2021 10-Q
19 03-11-2021 12-31-2020 10-K
20 11-09-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-11-2020 03-31-2020 10-Q
23 03-10-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 09-03-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 castle-biosciences-study-finds-15-of-barretts-esophagus-patients-face-higher-cancer-risk-than-pathology-suggests

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today anno...

 castle-biosciences-expands-decisiondx-scc-test-to-predict-local-recurrence-in-high-risk-skin-cancer-patients

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today anno...

 castle-biosciences-raises-fy2025-sales-guidance-from-28700m-29700m-to-31000m-32000m-vs-29410m-est

Castle Biosciences (NASDAQ:CSTL) raises FY2025 sales outlook from $287.00 million-$297.00 million to $310.00 million-$320.00 mi...

 castle-biosciences-q2-adj-eps-015-beats-049-estimate-sales-8619m-beat-7153m-estimate

Castle Biosciences (NASDAQ:CSTL) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $(...

 castle-biosciences-decisiondx-melanoma-test-granted-breakthrough-device-designation-by-fda

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today anno...

 castle-biosciences-signs-collaboration-and-license-agreement-with-scibase-to-develop-atopic-dermatitis-flare-prediction-test-using-electrical-impedance-spectroscopy-technology

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today anno...

 castle-biosciences-announces-it-will-present-research-aimed-at-enhancing-the-clinical-management-of-patients-with-cutaneous-melanoma-and-uveal-melanoma-at-the-2025-american-society-of-clinical-oncology-annual-meeting

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, will prese...

 scotiabank-maintains-sector-outperform-on-castle-biosciences-lowers-price-target-to-40

Scotiabank analyst Sung Ji Nam maintains Castle Biosciences (NASDAQ:CSTL) with a Sector Outperform and lowers the price targ...

 lake-street-maintains-buy-on-castle-biosciences-lowers-price-target-to-35

Lake Street analyst Thomas Flaten maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and lowers the price target from $40...

 canaccord-genuity-maintains-buy-on-castle-biosciences-lowers-price-target-to-37

Canaccord Genuity analyst Kyle Mikson maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and lowers the price target from...

 castle-biosciences-signs-definitive-agreement-to-acquire-capsulomics-terms-not-disclosed

Expected to complement Castle's current gastroenterology franchiseAdds methylation technology developed at the Johns Hopkin...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION